Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) was first reported in 2007. Following the development of crizotinib as a tyrosine kinase inhibitor (TKI) targeting ALK, the treatment of advanced NSCLC with ALK-rearrangements has made remarkable progress....

Descripción completa

Detalles Bibliográficos
Autores principales: Fukui, Takafumi, Tachihara, Motoko, Nagano, Tatsuya, Kobayashi, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909087/
https://www.ncbi.nlm.nih.gov/pubmed/35267492
http://dx.doi.org/10.3390/cancers14051184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909087/
https://www.ncbi.nlm.nih.gov/pubmed/35267492
http://dx.doi.org/10.3390/cancers14051184

Ejemplares similares